静脉阿替普酶治疗对血管内治疗中一线支架取栓器与单独抽吸技术效果的影响
该研究为MR CLEAN-NO IV试验的事后分析,纳入473例接受血管内治疗且尝试取栓的患者,比较一线支架取栓器(伴或不伴抽吸)与单独抽吸技术,并评估其与静脉阿替普酶治疗的交互作用。主要结局为90天改良Rankin量表评分。结果显示静脉阿替普酶与一线血管内治疗技术存在显著交互作用(P=0.03):单独抽吸组中,仅接受血管内治疗者功能结局较接受静脉阿替普酶联合血管内治疗者差(acOR 0.44,95%CI 0.21-0.90);支架取栓器组中,是否接受静脉阿替普酶功能结局无差异(acOR 1.08,95%CI 0.74-1.57)。
要点
- 在单独抽吸作为一线技术的患者中,未接受静脉阿替普酶者功能结局更差(acOR 0.44,95%CI 0.21-0.90)。
- 在支架取栓器作为一线技术的患者中,是否接受静脉阿替普酶功能结局无差异(acOR 1.08,95%CI 0.74-1.57)。
- 静脉阿替普酶与一线血管内治疗技术对功能结局存在显著交互作用(P=0.03)。
核心结论
- 在MR CLEAN-NO IV试验中,静脉阿替普酶的治疗效果被一线血管内治疗技术所修饰;以单独抽吸为一线技术且未接受静脉阿替普酶的患者临床结局更差,而支架取栓器组未见此种差异。
研究设计与样本
- 本研究为MR CLEAN-NO IV随机试验的事后分析,该试验比较静脉阿替普酶后血管内治疗与直接血管内治疗,纳入直接就诊于具备血管内治疗能力中心的患者。
- 共纳入473例接受血管内治疗并尝试取栓的患者,其中102例(21.6%)以单独抽吸为一线技术。
主要发现
- 在全人群中,支架取栓器与单独抽吸治疗的患者功能结局相似(校正共同比值比[acOR] 1.07,95%CI 0.69-1.66)。
- 静脉阿替普酶与一线血管内治疗技术之间存在显著交互作用(P=0.03)。
- 在单独抽吸组中,仅接受血管内治疗的患者功能结局较接受静脉阿替普酶联合血管内治疗者差(acOR 0.44,95%CI 0.21-0.90)。
- 在支架取栓器组中,接受与未接受静脉阿替普酶的患者功能结局无差异(acOR 1.08,95%CI 0.74-1.57)。
- 成功再灌注(扩展脑梗死溶栓评分2b-3)的交互作用无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需汇总其他试验结果以确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to assess whether the effect of intravenous alteplase treatment (IVT) before endovascular treatment (EVT) on outcome is modified by first-line technique during EVT in IVT eligible patients. METHODS: This was a post hoc analysis from MR CLEAN-NO IV (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands - Intravenous Treatment Followed by Intra-Arterial Treatment Versus Direct Intra-Arterial Treatment for Acute Ischemic Stroke Caused by a Proximal Intracranial Occlusion), a randomized trial of IVT followed by EVT versus EVT alone in patients presenting directly to EVT-capable centers. We included data from all patients who underwent EVT with a thrombectomy attempt. We compared patients treated with stent retriever (with or without aspiration) to aspiration alone as first-line EVT technique and assessed the interaction of first-line EVT technique with IVT treatment. Primary outcome was the 90-day modified Rankin Scale score, analyzed with mixed model ordinal regression for a shift towards better outcome. Secondary outcomes included successful reperfusion (extended Thrombolysis in Cerebral Infarction score 2b-3). RESULTS: Of 473 included patients, 102 (21.6%) were treated with aspiration alone as first-line technique. In the full population, functional outcome was similar for patients treated with stent retriever versus aspiration only (adjusted common odds ratio [acOR]' 1.07 [95% CI, 0.69-1.66]). We observed a significant interaction between IVT and first-line EVT technique (P=0.03). In the aspiration-only group, patients treated with EVT alone had worse functional outcome compared to those treated with IVT and EVT (acOR, 0.44 [95% CI, 0.21-0.90]). In the stent retriever group, functional outcome did not differ between patients treated with or without IVT (acOR, 1.08 [95% CI, 0.74-1.57]). There was no statistically significant interaction for successful reperfusion. CONCLUSIONS: In MR CLEAN-NO IV, the treatment effect of IVT was modified by first-line EVT technique. Patients treated with aspiration only as first-line technique had worse clinical outcomes if they did not receive IVT. No such difference was observed in patients treated with stent retrievers. Confirmation by pooling with results from other trials is needed to confirm these findings.
引用
- Rinkel LA, Treurniet KM, Nieboer D, et al. Effect of Intravenous Alteplase Treatment on First-Line Stent Retriever Versus Aspiration Alone During Endovascular Treatment. Stroke. 2022. PMID: 35876018. doi:10.1161/STROKEAHA.121.038390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。